Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab

Abstract High tumor expression of epidermal growth factor-like domain 7 (EGFL7) has been associated with a poor prognosis in colorectal cancer. The aim of the current study was to investigate the possible prognostic impact of circulating EGFL7 (cir-EGFL7), combined with single nucleotide polymorphis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Torben Frøstrup Hansen, Rikke Fredslund Andersen, Dorte Aalund Olsen, Flemming Brandt Sørensen, Anders Jakobsen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c33aa829b25342d9b52936e53781ac42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c33aa829b25342d9b52936e53781ac42
record_format	dspace
spelling	oai:doaj.org-article:c33aa829b25342d9b52936e53781ac422021-12-02T15:05:57ZPrognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab10.1038/s41598-017-02538-x2045-2322https://doaj.org/article/c33aa829b25342d9b52936e53781ac422017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02538-xhttps://doaj.org/toc/2045-2322Abstract High tumor expression of epidermal growth factor-like domain 7 (EGFL7) has been associated with a poor prognosis in colorectal cancer. The aim of the current study was to investigate the possible prognostic impact of circulating EGFL7 (cir-EGFL7), combined with single nucleotide polymorphism (SNP) analyses, in patients with metastatic colorectal cancer (mCRC) treated with first line chemotherapy and bevacizumab. A total of 88 patients were included. Serum was collected prior to treatment initiation, at first evaluation after 3 weeks, and at progression. Cir-EGFL7 was analysed by the enzyme-linked immunosorbent assay (ELISA) technique. The SNPs were analysed by real-time qPCR based on DNA from whole blood. Endpoints were response rate (RR), progression free survival (PFS), and overall survival (OS). Cir-EGFL7 decreases after administration of chemotherapy plus bevacizumab. Baseline levels of cir-EGFL7 were significantly related to PFS and OS, p = 0.0431 and p = 0.0017, respectively, with increasing cir-EGFL7 levels associated with a worse prognosis. Circulating EGFL7 was not associated with RR. The SNP analyses revealed a significant relationship between rs1051851 and OS, p = 0.030. This study demonstrates that cir-EGFL7 changes during treatment with chemotherapy plus bevacizumab and that baseline levels and genetic variations may influence the overall prognosis of patients with mCRC. The findings call for further validation.Torben Frøstrup HansenRikke Fredslund AndersenDorte Aalund OlsenFlemming Brandt SørensenAnders JakobsenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Torben Frøstrup Hansen Rikke Fredslund Andersen Dorte Aalund Olsen Flemming Brandt Sørensen Anders Jakobsen Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
description	Abstract High tumor expression of epidermal growth factor-like domain 7 (EGFL7) has been associated with a poor prognosis in colorectal cancer. The aim of the current study was to investigate the possible prognostic impact of circulating EGFL7 (cir-EGFL7), combined with single nucleotide polymorphism (SNP) analyses, in patients with metastatic colorectal cancer (mCRC) treated with first line chemotherapy and bevacizumab. A total of 88 patients were included. Serum was collected prior to treatment initiation, at first evaluation after 3 weeks, and at progression. Cir-EGFL7 was analysed by the enzyme-linked immunosorbent assay (ELISA) technique. The SNPs were analysed by real-time qPCR based on DNA from whole blood. Endpoints were response rate (RR), progression free survival (PFS), and overall survival (OS). Cir-EGFL7 decreases after administration of chemotherapy plus bevacizumab. Baseline levels of cir-EGFL7 were significantly related to PFS and OS, p = 0.0431 and p = 0.0017, respectively, with increasing cir-EGFL7 levels associated with a worse prognosis. Circulating EGFL7 was not associated with RR. The SNP analyses revealed a significant relationship between rs1051851 and OS, p = 0.030. This study demonstrates that cir-EGFL7 changes during treatment with chemotherapy plus bevacizumab and that baseline levels and genetic variations may influence the overall prognosis of patients with mCRC. The findings call for further validation.
format	article
author	Torben Frøstrup Hansen Rikke Fredslund Andersen Dorte Aalund Olsen Flemming Brandt Sørensen Anders Jakobsen
author_facet	Torben Frøstrup Hansen Rikke Fredslund Andersen Dorte Aalund Olsen Flemming Brandt Sørensen Anders Jakobsen
author_sort	Torben Frøstrup Hansen
title	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
title_short	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
title_full	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
title_fullStr	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
title_full_unstemmed	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
title_sort	prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/c33aa829b25342d9b52936e53781ac42
work_keys_str_mv	AT torbenfrøstruphansen prognosticimportanceofcirculatingepidermalgrowthfactorlikedomain7inpatientswithmetastaticcolorectalcancertreatedwithchemotherapyandbevacizumab AT rikkefredslundandersen prognosticimportanceofcirculatingepidermalgrowthfactorlikedomain7inpatientswithmetastaticcolorectalcancertreatedwithchemotherapyandbevacizumab AT dorteaalundolsen prognosticimportanceofcirculatingepidermalgrowthfactorlikedomain7inpatientswithmetastaticcolorectalcancertreatedwithchemotherapyandbevacizumab AT flemmingbrandtsørensen prognosticimportanceofcirculatingepidermalgrowthfactorlikedomain7inpatientswithmetastaticcolorectalcancertreatedwithchemotherapyandbevacizumab AT andersjakobsen prognosticimportanceofcirculatingepidermalgrowthfactorlikedomain7inpatientswithmetastaticcolorectalcancertreatedwithchemotherapyandbevacizumab
_version_	1718388669437444096

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab

Ejemplares similares